HDL and cardiovascular risk: Is cholesterol in particle subclasses relevant?

European Heart Journal

Volumn 36, Issue 1, 2015, Pages 10-12

  Gebhard, Catherine ^a   Rhainds, David ^a   Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TORCETRAPIB;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DENSITY GRADIENT CENTRIFUGATION; DYSLIPIDEMIA; FRACTIONATION; HEART INFARCTION; HUMAN; LIPID PEROXIDATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATIVE STRESS; PARTICLE SIZE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; CLASSIFICATION; FEMALE; MALE; MYOCARDIAL INFARCTION;

CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION;

EID: 84926284263     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu306     Document Type: Review

References (15)

1. Tuteja S, Rader DJ. High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm. Clin Pharmacol Ther 2014; 96: 48-56.
2. Martin SS, Khokhar AA, May HT, Kulkarni KR, Blaha MJ, Joshi PH, Toth PP, Muhlestein JB, Anderson JL, Knight S, Li Y, Spertus J, Jones SR. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur Heart J 2015; 36: 22-30.
3. Sweetnam PM, Bolton CH, Yarnell JW, Bainton D, Baker IA, Elwood PC, Miller NE. Associations of the HDL2andHDL3cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994; 90: 769-774.
4. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. Aprospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.NEngl JMed 1991; 325: 373-381.
5. Yu S, Yarnell JW, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003; 166: 331-338.
6. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011; 17: 594-603.
7. Arsenault BJ, Dube MP, Brodeur MR, de Oliveira Moraes AB, Lavoie V, Kernaleguen AE, Guauque-Olarte S, Mathieu P, Pibarot P, Messika-Zeitoun D, Bosse Y, Rhainds D, Rheaume E, Tardif JC. Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans. Arterioscler Thromb Vasc Biol 2014; 34: 457-462.
8. Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 2006; 52: 1722-1727.
9. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT, Schaefer EJ. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392-410.
10. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006; 58: 342-374.
11. Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23: 1881-1888.
12. de Souza JA, Vindis C, Negre-Salvayre A, Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ, Kontush A. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2010; 14: 608-620.
13. Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, Anzures-Cabrera J, Lehnert V, Pauly-Evers M, Holme I, Stasek J, van Hessen MW, Jones P. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 2014; 35: 1792-1800.
14. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJ. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51: 634-642.
15. Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, Connelly MA, Johnson WJ, Williams DL, Rothblat GH. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 2000; 275: 36596-36604.